Dosing for your patients with neutropenia

Neutropenia (Make a selection)

  • Mild to Moderate
  • Severe
  • Recurrent
MBC dose adjustments for neutropenia

Illustrative purposes only.

Mild to Moderate

  • If neutropenia is mild or moderate (Grade 1 or 2), no dose reduction is needed
MBC dose adjustments for neutropenia

Illustrative purposes only.

Severe

  • If neutropenia is severe (neutrophils <500 cells/mm3 for 7 days or longer), reduce dose from 260 mg/m2 to 220 mg/m2 for subsequent courses
MBC dose adjustments for neutropenia

Illustrative purposes only.

Recurrent

  • If severe neutropenia is recurrent, reduce dose from 220 mg/m2 to 180 mg/m2 for subsequent courses
  • In the phase 3 ABRAXANE MBC clinical trial, neutropenia (<2.0×109/L) occurred in 80% of patients receiving ABRAXANE 260 mg/m2 over 30 minutes; neutropenia (<0.5×109/L) occurred in 9% of patients receiving ABRAXANE

Dosing for your patients with neutropenia

Neutropenia (Make a selection)

  • Mild to Moderate
  • Severe
  • Recurrent
MBC dose adjustments for neutropenia

Mild to Moderate

  • If neutropenia is mild or moderate (Grade 1 or 2), no dose reduction is needed
MBC dose adjustments for neutropenia

Severe

  • If neutropenia is severe (neutrophils <500 cells/mm3 for 7 days or longer), reduce dose from 260 mg/m2 to 220 mg/m2 for subsequent courses
Metastatic breast cancer dose adjustments for neutropenia

Recurrent

  • If severe neutropenia is recurrent, reduce dose from 220 mg/m2 to 180 mg/m2 for subsequent courses

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.